Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | GOT1 | P17174 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23207913 | 0.89 | STING1 (0.62) | STING1IGF1RIKBKBCHUKLYN | |
| SCHEMBL30195943 | 0.89 | STING1 (0.62) | STING1IGF1RIKBKBCHUKLYN | |
| SCHEMBL23207670 | 0.84 | STING1 (0.48) | STING1RIPK1IGF1RIKBKBCHUK | |
| SCHEMBL30195946 | 0.81 | STING1 (0.60) | STING1IGF1RIKBKBCHUKLYN | |
| SCHEMBL23208029 | 0.81 | STING1 (0.60) | STING1IGF1RIKBKBCHUKLYN | |
| SCHEMBL30885396 | 0.81 | STING1 (0.46) | STING1LYNPLK4TRPV1 | |
| SCHEMBL23208227 | 0.80 | STING1 (0.62) | STING1IGF1RIKBKBCHUKLYN | |
| SCHEMBL23207908 | 0.78 | STING1 (0.58) | STING1IGF1RIKBKBCHUKLYN | |
| SCHEMBL23208031 | 0.78 | STING1 (0.58) | STING1IGF1RGOT1TRPV1 | |
| SCHEMBL30196123 | 0.78 | STING1 (0.58) | STING1IGF1RIKBKBCHUKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2021067801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885RIPK1 230/4885TEK 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.